CROWN研究3年随访更新:洛拉替尼一线治疗ALK阳性晚期非小细胞肺癌的疗效与安全性
CROWN是一项国际随机开放标签3期试验,纳入296例未经系统治疗的ALK阳性晚期非小细胞肺癌患者,随机接受洛拉替尼或克唑替尼。
要点
- 洛拉替尼一线治疗显著改善无进展生存期,3年无进展生存率64% vs 19%。
- 无论基线有无脑转移,洛拉替尼均显著延迟颅内进展。
- 洛拉替尼组3-4级不良事件发生率76%,最常见为血脂异常。
核心结论
- 长期随访数据显示洛拉替尼较克唑替尼在未经治疗的ALK阳性晚期非小细胞肺癌中具有持久的疗效获益。
- 结果支持洛拉替尼作为一线治疗用于伴或不伴基线脑转移的患者。
研究设计与样本
- CROWN为正在进行的国际、随机、开放标签3期试验,在23个国家104个中心开展。
- 纳入296例晚期ALK阳性非小细胞肺癌患者,随机1:1接受洛拉替尼100 mg每日一次或克唑替尼250 mg每日两次。
- 本次为3年随访后的非计划分析,描述性呈现肿瘤相关终点。
主要发现
- 3年无进展生存率:洛拉替尼组64%(95% CI 55-71),克唑替尼组19%(95% CI 12-27)。
- 无脑转移患者中,洛拉替尼组1例(1%) vs 克唑替尼组25例(23%)出现颅内进展。
- 3-4级不良事件:洛拉替尼组113/149例(76%),克唑替尼组81/142例(57%);因不良事件停药分别为11例(7%)和14例(10%)。
临床怎么用
- 对于未经治疗的ALK阳性晚期非小细胞肺癌,可优先考虑洛拉替尼一线治疗。
- 洛拉替尼对基线脑转移患者具有显著的颅内保护作用,支持其用于脑转移患者。
- 用药期间需关注血脂异常等3-4级不良事件,但整体安全性可控。
局限性
- 本次为非计划分析,无进展生存期等终点仅作描述性呈现。
- 中位无进展生存期在洛拉替尼组未达到,长期获益仍需继续随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After a median follow-up of 18·3 months, the third-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in patients with treatment-naive, ALK-positive non-small-cell lung cancer in the phase 3 CROWN study. Here we report updated efficacy data, including intracranial activity, from an unplanned analysis after 3 years of follow-up. METHODS: CROWN is an ongoing, international, randomised, open-label phase 3 trial done in 104 centres in 23 countries worldwide. Eligible participants were aged 18 years and older or aged 20 years and older (depending on local regulations) with advanced, ALK-positive non-small-cell lung cancer, had received no previous systemic treatment for metastatic disease, had at least one extracranial measurable target lesion (according to the Response Evaluation Criteria in Solid Tumours [RECIST], version 1.1), and had an Eastern Cooperative Oncology Group performance status score of 0-2. Patients were randomly assigned (1:1) to oral lorlatinib 100 mg daily or oral crizotinib 250 mg twice daily in 28-day cycles. Randomisation was stratified by the presence or absence of brain metastasis, and by ethnicity. Since the primary endpoint of the study had been met at the planned interim analysis, no further formal analysis of progression-free survival was planned, per protocol. The current unplanned analysis was done to further characterise tumour-related endpoints with a longer follow-up and is presented descriptively. For the planned study, the primary endpoint was progression-free survival assessed by blinded independent central review. Secondary endpoints included progression-free survival (investigator), objective response rate, intracranial objective response rate, time to intracranial progression, duration of response, intracranial duration of response, and safety. Efficacy endpoints were also assessed by the presence or absence of baseline brain metastases. This study is registered with ClinicalTrials.gov, NCT03052608. FINDINGS: Between May 11, 2017, and Feb 28, 2019, 425 patients were screened for eligibility, of whom 296 were enrolled and randomly assigned to the lorlatinib (n=149) or crizotinib (n=147) group. At data cutoff for this unplanned analysis (Sept 20, 2021), median duration of follow-up for progression-free survival was 36·7 months (IQR 31·3-41·9) for lorlatinib and 29·3 months (10·8-35·0) for crizotinib. Median progression-free survival by blinded independent central review was not reached (95% CI not reached-not reached) for lorlatinib and was 9·3 months (7·6-11·1) for crizotinib (hazard ratio [HR] 0·27 [95% CI 0·18-0·39]). 3-year progression-free survival was 64% (95% CI 55-71) in the lorlatinib group and 19% (12-27) in the crizotinib group. Progression-free survival (investigator), objective response rate, intracranial objective response rate, time to intracranial progression, and duration of response were improved with lorlatinib versus crizotinib. In patients with baseline brain metastases (n=37 lorlatinib; n=39 crizotinib), the HR for time to intracranial progression for lorlatinib versus crizotinib was 0·10 (95% CI 0·04-0·27); in patients without baseline brain metastases (n=112 lorlatinib; n=108 crizotinib), the HR was 0·02 (95% CI 0·002-0·14). In patients without brain metastases, one (1%) in the lorlatinib group and 25 (23%) in the crizotinib group had intracranial progression. Grade 3-4 adverse events occurred in 113 (76%) of 149 patients (most commonly due to altered lipid levels) with lorlatinib and in 81 (57%) of 142 patients with crizotinib. Adverse events led to treatment discontinuation in 11 (7%) patients in the lorlatinib group and 14 (10%) patients in the crizotinib group. There were no new safety signals. INTERPRETATION: These updated, long-term data from CROWN show the durable benefit of lorlatinib over crizotinib in patients with treatment-naive, ALK-positive non-small-cell lung cancer and support the use of first-line lorlatinib in patients with and without baseline brain metastases. FUNDING: Pfizer.
引用
- Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2022. PMID: 36535300. doi:10.1016/S2213-2600(22)00437-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。